Many think the next standard cancer treatment will pair two innovations.
The increasingly more popular combination of Padcev and Keytruda has expanded its bladder cancer territory once again. | The ...
Merck & Co.’s almighty Keytruda has become the first PD-1 inhibitor to show a benefit as a single agent for the front-line treatment of a subtype of endometrial cancer. | Merck & Co.’s almighty ...
Merck & Co.'s cancer immunotherapy Keytruda is one of the pharmaceutical industry's biggest successes. The drug's arrival in 2014 introduced a new way of treating cancer and, over time, it became ...
Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in ...
SLS leads in stock momentum, while MLTX is cheaper and better-funded, with nearly $300 million in cash at the end of the ...
The KEYNOTE-671 trial showed a 71% 36-month overall survival rate with perioperative Keytruda, compared to 64% with placebo. FDA approvals for Keytruda, Imfinzi, and Opdivo in perioperative settings ...
At five years, KEYTRUDA plus LENVIMA showed a 16.7% overall survival (OS) rate for these patients with mismatch repair proficient (pMMR) advanced endometrial carcinoma versus 7.3% for chemotherapy ...
Prescription drugs purchased under a controversial government discount program amounted to $100 billion in 2025, a 22.8% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results